| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6001657 | Thrombosis Research | 2014 | 4 Pages |
Abstract
KRAS mutation is associated with an increased risk of VTE in this NSCLC cohort. These findings are consistent with preclinical studies. Prospective data on VTE rates from clinical trials with molecularly defined NSCLC are needed to confirm these findings.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Luis Corrales-Rodriguez, Denis Soulières, Xiaoduan Weng, Mustapha Tehfe, Marie Florescu, Normand Blais,